AMGN Amgen Inc.

438.82USD-1.14%Mkt Cap: 237.36B USDP/E: 25.44

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthriti…

Institutional holders20 on file

Key Statistics

Company
Market Cap237.36B USD
Enterprise Value280.92B USD
Revenue (TTM)38.90B USD
Gross Profit24.71B USD
Net Income (TTM)7.71B USD
Revenue/Share72.11 USD
Last Price438.82 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees31.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)25.44
P/E (Forward)17.50
PEG2.61
EV/EBITDA15.93
EV/Revenue7.22
P/S6.10
P/B16.54
EPS (TTM)17.25 USD
EPS (Forward)25.08 USD
52W Range
312.3974% of range483.99
52W High483.99 USD
52W Low312.39 USD
Profitability
Gross Margin67.25%
Oper. Margin34.12%
EBITDA Margin45.32%
Profit Margin20.98%
ROE89.06%
ROA8.51%
ROIC14.41%
ROCE13.95%
Growth
Revenue Growth8.50%
Earnings Growth19.40%
Cash Flow & Leverage
Operating CF9.96B USD
CapEx (TTM)1.86B USD
FCF Margin18.96%
FCF Yield3.11%
Net Debt40.82B USD
Net Debt/EBITDA2.31
Net Debt/FCF5.53
Balance Sheet
Debt/Equity6.31
Current Ratio1.48
Quick Ratio1.01
Book Value/Sh26.53 USD
Cash/Share24.39 USD
Dividends
Fwd Div Rate10.08 USD
Trail. Div Rate9.94 USD
Div. Yield2.27%
5Y Avg Yield2.98%
Payout Ratio57.62%
Ex-Div DateNov 20, 2026
Pay DateDec 11, 2026
Splits
Last Split2:1
Split DateNov 22, 1999
Analyst Consensus
Rating2.7 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)435.77 USD
Upside (mean)-0.7%
Target Range230.00 USD – 542.00 USD
230.00-0.7% to mean542.00
# Analysts29
Ownership
Shares Out.540.91M
Float539.44M
Insiders0.24%
Institutions84.65%
Short Interest
Short Ratio4.7d
Short % Float2.33%
Short % Out.2.33%
Shares Short12.59M
Short (prev mo.)14.03M
Technical
SMA 50425.81 (+3.1%)
SMA 200381.61 (+15.0%)
Beta0.42
S&P 52W Chg12.08%
Avg Vol (30d)2.51M
Avg Vol (10d)2.70M
Technical Indicators
RSI (14)42.8
MACD5.5054
MACD Signal9.7866
MACD Hist.-4.2812
BB Upper479.88 USD
BB Middle458.53 USD
BB Lower437.18 USD
BB Width9.31%
ATR (14)11.61 USD
Vol Ratio (20d)1.00x

About Amgen (NASDAQ: AMGN)

›

Amgen (NASDAQ: AMGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 31,500 employees.

The shares were at 438.82 USD on 19 November 2026, up 42.1% over 52 weeks. Its 52-week range is 312.39 USD to 483.99 USD: the price is 9.3% below the high and 40.5% above the low.

At a market capitalisation of 237.36B USD, it trades at 25.4 times trailing earnings and 17.5 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, so AMGN is valued in line with them. It pays a dividend yielding 2.27% (it pays out 58% of its earnings), against a median of 2.55% among the dividend payers in that peer group.

Amgen reports return on equity of 89.1%, an operating margin of 34.1% and revenue up 8.5% year over year.

Its debt exceeds its cash by 40.82B USD, a debt-to-equity ratio of 6.31. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 29 analysts cover the stock, with an average rating of Hold; their mean price target of 435.77 USD is 0.7% below the current price. The next earnings report is expected on 2 February 2027.